Phase III trials for Tranzyme and Norgine's ulimorelin
This article was originally published in Scrip
Executive Summary
Tranzyme Pharma and Norgine have started Phase III testing of their investigational ghrelin agonist ulimorelin for post-operative ileus (POI), chasing a market currently dominated by Adolor's alvimopan (Entereg).